Generate Biomedicines CEO buys 20,000 GENB shares

Generate Biomedicines, Inc. Chief Executive Officer Michael Nally purchased 20,000 shares of common stock in an open-market transaction at $12.00 per share.

Accepted by SEC EDGAR 03/06/2026 - 04:55 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Generate Biomedicines, Inc. Chief Executive Officer Michael Nally purchased 20,000 shares of common stock in an open-market transaction at $12.00 per share. Following this purchase, he directly owned 572,707 common shares, with additional indirect holdings reported through the MTN 2024 GST Trust and MTN 2024 GRAT.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Nally Michael

Role Chief Executive Officer

Bought 20,000 shs ($240K)

Increase in Position 3.6%

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,000	$12.00	$240K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 572,707 shares (Direct); Common Stock — 1,316,654 shares (Indirect, By MTN 2024 GST Trust); Common Stock — 999,793 shares (Indirect, By MTN 2024 GRAT)

Holdings Before and After: Common Stock, 552,707 to 572,707 shares (Direct)

Other Insiders: 4 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GENB CEO Michael Nally report on this Form 4?

Michael Nally reported buying 20,000 shares of Generate Biomedicines common stock in an open-market transaction at $12.00 per share. This filing reflects a direct increase in his ownership stake through a straightforward purchase of additional GENB shares on March 4, 2026.

How many GENB shares does Michael Nally own directly after this transaction?

After the reported purchase, Michael Nally directly owns 572,707 shares of Generate Biomedicines common stock. This figure reflects his direct holdings only and does not include indirect shares reported as held through related entities such as the MTN 2024 GST Trust and the MTN 2024 GRAT.

At what price did the GENB CEO buy his additional common shares?

Michael Nally purchased the additional 20,000 Generate Biomedicines common shares at a price of $12.00 per share. This open-market transaction price provides a clear reference level for the insider’s recent buying activity in the company’s common stock on that date.

What indirect GENB shareholdings related to Michael Nally are disclosed?

The filing discloses indirect holdings of Generate Biomedicines common stock through entities identified as the MTN 2024 GST Trust and the MTN 2024 GRAT. These positions are reported as indirect ownership, separate from Nally’s directly held shares following his recent open-market purchase.

Does the Form 4 mention any disclaimer about Michael Nally’s beneficial ownership?

Yes. The filing includes a disclaimer stating that Michael Nally disclaims beneficial ownership of certain shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest, and that the report should not be deemed an admission of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nally Michael

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		P		20,000	A	$12	572,707	D
Common Stock								1,316,654	I	By MTN 2024 GST Trust(1)
Common Stock								999,793	I	By MTN 2024 GRAT(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Michael Wolf, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.